Trade

with

Exact Sciences Corp
(NASDAQ: EXAS)
AdChoices
24.00
+0.18
+0.76%
After Hours :
-
-
-

Open

24.21

Previous Close

23.82

Volume (Avg)

1.70M (2.31M)

Day's Range

23.53-24.32

52Wk Range

10.46-26.79

Market Cap.

1.98B

Dividend Rate ( Yield )

-

Beta

1.37

Shares Outstanding

82.93M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 4.14M

    • Net Income

    • -46.51M

    • Market Cap.

    • 1.98B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -2,489.01

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.37

    • Forward P/E

    • -27.47

    • Price/Sales

    • 769.23

    • Price/Book Value

    • 8.15

    • Price/Cash flow

    • -37.88

      • EBITDA

      • -45.03M

      • Return on Capital %

      • -28.11

      • Return on Equity %

      • -29.71

      • Return on Assets %

      • -28.11

      • Book Value/Share

      • 2.93

      • Shares Outstanding

      • 82.93M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 26.00

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • -0.84

        • Cashflow Estimate

        • -1.01

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -71.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -2,489.01

            • 39.38

            • Net Profit Margin

            • -2,489.01

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 99.70

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -696.90

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.00

              • 0.76

              • Current Ratio

              • 24.32

              • 2.92

              • Quick Ratio

              • 23.91

              • 2.35

              • Interest Coverage

              • -980.50

              • 38.02

              • Leverage Ratio

              • 1.05

              • 2.21

              • Book Value/Share

              • 2.93

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -29.59

                • 238.10

                • P/E Ratio 5-Year High

                • -33.50

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.90

                • 124.82

                • Price/Sales Ratio

                • 714.29

                • 8.94

                • Price/Book Value

                • 8.07

                • 8.12

                • Price/Cash Flow Ratio

                • -37.88

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -29.71

                    (-131.60)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -28.11

                    (-38.50)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -29.42

                    (-95.80)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.01

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -46.76M
                  Operating Margin
                  -1,128.40
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -37.88
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  44.04%

                  Mutual Fund Ownership

                  52.04%

                  Float

                  99.03%

                  5% / Insider Ownership

                  2.45%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,258,602

                  • 75.33

                  • 2.72

                  • First Trust NYSE Arca Biotech Fund

                  •  

                    2,139,355

                  • -56.13

                  • 3.16

                  • Wasatch Small Cap Growth Fund

                  •  

                    1,621,982

                  • 0.00

                  • 1.96

                  • Vanguard Explorer Fund

                  •  

                    1,474,177

                  • 18.22

                  • 1.78

                  • Vanguard Small Cap Index

                  •  

                    1,440,545

                  • -0.17

                  • 1.74

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,348,301

                  • 0.00

                  • 1.63

                  • iShares Russell 2000 (AU)

                  •  

                    1,298,926

                  • -0.68

                  • 1.92

                  • Goldman Sachs Small Cap Value

                  •  

                    1,273,073

                  • -27.05

                  • 1.54

                  • Invesco Small Cap Growth Fund

                  •  

                    1,102,600

                  • 86.07

                  • 1.30

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    5,021,253

                  • +14.40%

                  • 6.06

                  • Gilder Gagnon Howe & CO LLC

                  •  

                    4,514,017

                  • -0.86%

                  • 5.44

                  • First Trust Advisors L.P.

                  •  

                    4,491,304

                  • +10.55%

                  • 5.42

                  • Invesco Advisers, Inc

                  •  

                    3,404,134

                  • +55.27%

                  • 4.11

                  • Blair William & Co

                  •  

                    3,094,114

                  • +254.86%

                  • 3.73

                  • Wasatch Advisors Inc.

                  •  

                    2,960,068

                  • -0.32%

                  • 3.57

                  • Goldman Sachs Asset Management, L.P.

                  •  

                    2,586,114

                  • -15.74%

                  • 3.12

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Growth

                  Exact Sciences Corp was incorporated in the State of Delaware on February 10, 1995. The company is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company’s Cologuard test is de...moresigned to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer and is expected to be a powerful, preventive tool. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, Company completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada. All patients provided a sample to be tested with Cologuard test, and received a FIT test and a colonosco...morepy. As of December 31, 2013, Company owned 10 issued patents and 28 pending patent applications in the United States, and 62 issued patents and 26 pending patent applications in foreign jurisdictions. In addition, as part of its 2009 strategic transaction with Genzyme Corporation, it received an exclusive license back from Genzyme Corporation in the fields of colorectal cancer screening and stool-based detection of any disease or condition to the 26 patents issued and 7 pending patent applications in the U.S., and 29 patents issued and 12 pending patent applications in foreign jurisdictions sold to Genzyme. Certain of its activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products. sDNA testing faces competition from procedure-based detection technologies such as flexible sigmoidoscopy, colonoscopy and virtual colonoscopy.lessless

                  Key People

                  Kevin T. Conroy

                  CEO/Chairman of the Board/Director/President

                  Mr. William Megan

                  CFO/Senior VP, Divisional

                  Ms. Sally W. Crawford

                  Director

                  David A. Thompson

                  Director

                  Mr. Lionel N. Sterling

                  Director

                  • Exact Sciences Corp

                  • 441 Charmany Drive

                  • Madison, WI 53719

                  • USA.Map

                  • Phone: +1 608 284-5700

                  • Fax: +1 608 284-5701

                  • exactsciences.com

                  Incorporated

                  1995

                  Employees

                  102

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: